Switch theme
Sign up to access all valuation multiples
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
2004
159
LTM Revenue $4.2M
LTM EBITDA -$67.7M
-$32.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Molecular Partners has a last 12-month revenue of $4.2M and a last 12-month EBITDA of -$67.7M.
In the most recent fiscal year, Molecular Partners achieved revenue of $5.6M and an EBITDA of -$58.4M.
Molecular Partners expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Molecular Partners valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $8.0M | $5.6M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$67.3M | -$58.4M | XXX | XXX | XXX |
| EBITDA Margin | -846% | -1039% | XXX | XXX | XXX |
| Net Profit | $133M | -$70.1M | XXX | XXX | XXX |
| Net Margin | 1675% | -1247% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Molecular Partners's stock price is CHF 3 (or $4).
Molecular Partners has current market cap of CHF 118M (or $134M), and EV of -CHF 28.6M (or -$32.4M).
See Molecular Partners trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$32.4M | $134M | XXX | XXX | XXX | XXX | $-1.78 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Molecular Partners has market cap of $134M and EV of -$32.4M.
Molecular Partners's trades at -7.7x LTM EV/Revenue multiple, and 0.5x LTM EBITDA.
Analysts estimate Molecular Partners's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Molecular Partners and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$32.4M | XXX | XXX | XXX |
| EV/Revenue | -5.8x | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | XXX | XXX |
| P/E | -2.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMolecular Partners's NTM/LTM revenue growth is -48%
Molecular Partners's revenue per employee for the last fiscal year averaged $35K, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Molecular Partners's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Molecular Partners's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Molecular Partners and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -29% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1039% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1087% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $35K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 345% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 978% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1332% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Molecular Partners acquired XXX companies to date.
Last acquisition by Molecular Partners was XXXXXXXX, XXXXX XXXXX XXXXXX . Molecular Partners acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Molecular Partners founded? | Molecular Partners was founded in 2004. |
| Where is Molecular Partners headquartered? | Molecular Partners is headquartered in Switzerland. |
| How many employees does Molecular Partners have? | As of today, Molecular Partners has 159 employees. |
| Who is the CEO of Molecular Partners? | Molecular Partners's CEO is Dr. Patrick Amstutz, PhD. |
| Is Molecular Partners publicy listed? | Yes, Molecular Partners is a public company listed on SWX. |
| What is the stock symbol of Molecular Partners? | Molecular Partners trades under MOLN ticker. |
| When did Molecular Partners go public? | Molecular Partners went public in 2014. |
| Who are competitors of Molecular Partners? | Similar companies to Molecular Partners include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Molecular Partners? | Molecular Partners's current market cap is $134M |
| What is the current revenue of Molecular Partners? | Molecular Partners's last 12-month revenue is $4.2M. |
| What is the current EBITDA of Molecular Partners? | Molecular Partners's last 12-month EBITDA is -$67.7M. |
| What is the current EV/Revenue multiple of Molecular Partners? | Current revenue multiple of Molecular Partners is -7.7x. |
| What is the current EV/EBITDA multiple of Molecular Partners? | Current EBITDA multiple of Molecular Partners is 0.5x. |
| What is the current revenue growth of Molecular Partners? | Molecular Partners revenue growth between 2023 and 2024 was -29%. |
| Is Molecular Partners profitable? | Yes, Molecular Partners is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
